U.S. Specialized REITs Stock News

Ziff Davis stock jumped 5.7% to US$53.87 into the earnings close, which is a strong move for a company that is still reporting losses from continuing operations. The headline is not the loss. It is the sudden cash firepower created by the US$1.2b sale of the Connectivity business, paired with heavy share repurchases that have already cut the share count by about 11% this year. What you are seeing is a market trying to price a balance sheet and valuation story rather than a clean growth story...

Vistance Networks just jumped 8.3% to US$10.94 in the first full session after earnings, a sharp move for a stock that had been down over the past month and quarter. The headline is not growth at any cost. The story is a profit squeeze in a capital intensive telecom equipment business that needs healthy margins to fund its product roadmap. Q2 adjusted EBITDA for Vistance Networks’ continuing operations came in at US$36m on US$320m of net sales, while Aurora Networks’ EBITDA dropped much...

American Realty Investors shares edged 2.5% higher to US$15.36 after the Q2 release, even though the headline story was fresh pressure on profitability. The stock came into earnings after a weak 30 day stretch, and traders quickly focused on the company’s still positive trailing 12 month earnings. The real tension is between that profitable trailing picture and the quarterly income statement, which showed a small loss alongside modest revenue of US$12.9m. With a P/E of 29.7x, sitting above...

Advanced Drainage Systems dropped about 3% today, which looks odd when you line it up against what just happened in the business. The stock came into this earnings print after a flat month and a modest gain over the past quarter. Yet the company just booked roughly US$1.0b in quarterly revenue and one of its highest ever adjusted earnings before interest, tax, depreciation and amortization margins at 35.8%. The short term mood is cautious. The longer term story is that Advanced Drainage...

Novavax stock inched up about 3% to US$7.95 into the Q2 print, a modest move for a biotech that just posted another quarterly loss. The headline this quarter is not the loss itself. It is the pressure on the income statement as revenue for Q2 came in at US$56.7m and net loss reached US$53.4m. In the very short term traders are reacting to that mix of revenue and red ink. Long term holders are more likely focused on the gap between the current P/S multiple and valuation models that point to a...

Elevance Health stock has delivered a strong 36.9% return over the past year, and the current valuation checks now raise the question of whether that strength is still backed by a discount or already reflected in the price. Over the last 12 months, Elevance Health is up 36.9%, which puts recent buyers in a comfortable position and makes entry price more important for anyone considering the stock today. The company’s push to strengthen its connected cancer care model can support longer term...

Intellia Therapeutics stock jumped 6.2% to US$11.94 after earnings, which suggests investors heard something they liked from a gene editing story that has delivered sharp volatility in recent months. The headline is simple: the science stepped forward while the income statement stayed firmly in loss-making territory. Q2 revenue came in at US$7.7m and Intellia reported a net loss of US$106.6m. The cash pile of US$628.4m and management’s stated runway into at least 2028 now sit at the center of...

PRA Group stock jumped 9% to US$19.79 after the Q2 release, a sharp move for a consumer finance recovery specialist that has spent the past year in the red on a trailing basis. Traders reacted to one clear headline: core collections and balance sheet economics point to a rebuilding earnings engine, with Q2 net income of US$57.9m and basic earnings per share of US$1.52. The short term pop matters if you are trading the chart. The bigger story is whether this quarter marks the first credible...

Emergent BioSolutions came into this earnings print as a beaten down biotech, with the stock already down sharply over the past three months and now dropping another 8.9% to about US$4.84 after the release. The headline is not the top line. Q2 revenue of US$234.3m and adjusted EBITDA strength from its Medical Countermeasures business landed against a stark reality on the income statement. The company reported a Q2 net loss of US$180.2m, driven in large part by a large non cash impairment tied...

What Sanmina’s Latest Earnings Mean For Investors Sanmina (SANM) has stepped into the spotlight after reporting third quarter sales of US$3.46b and net income of US$117.13m, alongside raised full year revenue guidance and inclusion in the Zacks Rank #1 growth stocks list. These updates provide fresh data points that investors can use to assess whether the recent share performance and current valuation align with the company’s earnings profile and growth characteristics. See our latest...

Red Cat Holdings stock jumped 6.2% to US$9.21 into the first full session after earnings, yet the mood around the stock is anything but relaxed. Traders are cheering the aerospace and defense drone specialist for one headline figure. Quarterly revenue landed at US$20.2m, with reported gross margin at 16.1%, which stands out in a sector where volume and unit economics can quickly swing sentiment. The catch is that Red Cat Holdings is still posting sizeable net losses and carries a rich P/S...

Verastem walked into this earnings print with a stock that had already been heating up, yet the market still punched the gas. Shares jumped about 14% to US$6.74 after the Q2 release. That kind of move in a volatile biotech usually signals investors see something more durable than a one quarter bump. The headline is clear for Verastem. Product revenue in Q2 reached about US$25.1m and total revenue for the quarter was a little over US$40m, while the company still reported a sizeable net loss...

ATI shareholders woke up to a 2% gain today, which looks modest compared with the strength of the latest aerospace heavy earnings print. The stock comes into this report already riding sharp momentum over the past quarter, yet the market reaction still feels restrained, given a headline quarter built on higher revenue of about US$1.3b and a clear jump in basic earnings per share. The real story is margin power. Adjusted EBITDA of US$284m and a 22.6% margin in Q2 turned ATI’s long running...

Tariff refunds worth an estimated $100b are now flowing back to giants like Apple, Ford and Amazon after the Supreme Court overturned parts of the Trump era trade policy. Some companies are signalling they will share at least some of the savings with shoppers. Others are keeping quiet. For investors, that mix of legal rulings, policy uncertainty and possible pricing shifts creates fresh openings. This article walks through 3 large cap consumer and retail stocks from the screener that stand...

The market shrugged off Liberty Live Holdings' latest quarter with a mild 0.9% slide, but the earnings story is far louder than that single day move suggests. This stock has been priced as a high growth entertainment play, yet Q2 still rested on heavy losses and a stretched valuation. Liberty Live reported Q2 revenue of US$147.1m alongside a net loss of US$268.7m, keeping earnings per share deep in the red. With a P/S multiple around 26x compared with much lower industry levels, the results...

GigaCloud Technology stock barely flinched after earnings, up about 1.6% to US$53.25, even though the report highlighted clear top line and profit strength. Revenue for Q2 landed at about US$411.6m with net income of US$42.3m, and the company stayed debt free with US$379m of liquidity. The muted one day move suggests investors treated this as confirmation rather than a fresh catalyst. With trailing P/E near 12.5x and a buyback program in place, the market reaction points more to cautious...

TriSalus Life Sciences just jumped 15.2% to US$5.61, yet the quarter itself reads more like a profitability reset than a clean win. The stock had already been on a strong run over the past month, so this move reflects relief as much as excitement. The headline is simple: Q2 revenue reached US$11.4m and gross margin sat at a high 86.8%, but TriSalus reported a net loss of US$9.2m and a wider adjusted EBITDA loss of about US$7.1m as sales and marketing spending climbed. The real story is the...

Ryman Hospitality Properties shares slipped about 3% to US$120.84 after the Q2 release, even though the core real estate metric told a stronger story. Funds From Operations, the key cash flow gauge for a hotel and resort REIT, reached US$143.5 million in Q1 and was more than US$510 million on a trailing twelve month basis. Revenue for Q2 was US$748.9 million. The short term price weakness contrasts with a company generating substantial cash flow, which keeps attention on how investors weigh...

CytomX Therapeutics stock edged up about 3% to US$3.46 into this post earnings lull, even though the headline numbers lean more sobering than celebratory. Quarterly revenue came in at US$1.4 million and the company reported a net loss of US$20.7 million, which keeps the long running profitability debate very much alive. The real focus is the contrast between a modest one day bounce and a business model that still leans heavily on future drug success and an already rich P/S multiple. The...

PDF Solutions stock jumped 7.7% to US$49.45 after the Q2 print, a sharp move for a company that had been roughly flat over the past week and soft over the past month. The market latched onto one headline. Earnings power is building faster than many expected, with Q2 net income of US$4.3m and a trailing net profit margin of 4.3% that sits well above last year. The near term story is the pop in the share price. The real story is the multi quarter shift from break even quarters toward consistent...

Guardian Pharmacy Services just rose 11% to US$43.83, even though the headline number was not a blowout on revenue. The market is focusing on one thing: profitability is firming up. Net income reached US$21.9m, while adjusted earnings before interest, tax, depreciation and amortization was US$29.7m with an 8.4% margin. For a long term care pharmacy operator, where reimbursement pressure usually squeezes every basis point of margin, that increase in earnings power is a key part of the story...

Cable One came into this earnings print as a deeply sold off broadband stock, with the share price already under pressure over the past quarter. The Q2 release then hit with a shock, and the stock dropped another 16.1% on Friday after investors absorbed a sharp quarterly net loss and a step down in adjusted earnings power. The main takeaway is straightforward. Revenue of US$348.9m sat against a net loss of US$1,164.6m and an adjusted EBITDA margin that slipped below 50%. The market is...

Deep Isolation Nuclear just saw its stock drop 11.1% in a single session, yet the headline from this quarter is not a sudden collapse in demand. The shock is how thin the financial cushion now looks for a business still trying to prove its model. Q2 revenue came in at about US$1.3 million, while the company booked a net loss of roughly US$3.0 million and remains unprofitable over the past 12 months. With less than a year of cash runway and a rich P/S multiple, today’s selloff reads as a...

Navient stock dropped 4.3% to US$9.08 in the first session after earnings, even as the quarter marked a clear shift back into cleaner profitability. The company delivered Q2 2026 basic earnings per share of US$0.27 and net income of US$25 million, building on the prior quarter and a difficult 2025. For a student loan specialist long viewed through the lens of credit risk and regulation, the real headline is tighter cost control and a more focused loan book that helped lift core earnings, even...